A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors - Trial NCT06311578
Access comprehensive clinical trial information for NCT06311578 through Pure Global AI's free database. This Phase 1 trial is sponsored by Johnson & Johnson Enterprise Innovation Inc. and is currently Recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 66 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Johnson & Johnson Enterprise Innovation Inc.
Timeline & Enrollment
Phase 1
Apr 10, 2024
Nov 30, 2033
Primary Outcome
Part 1: Number of Participants with Dose-Limiting Toxicity (DLT),Number of Participants with Adverse Events (AEs) by Severity
Summary
The purpose of this study is to determine the safety, feasibility, recommended dose(s) and
 regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06311578
Non-Device Trial